Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting

Autor: Michiel Sedelaar, Jochem R.N. van der Voort van Zyp, Jeroen Kneppers, Sjoerd O. Klaver, Jeroen van Moorselaar, Niven Mehra, Stijn W.T.P.J. Heijmink, Herman Stoevelaar, Shafak S Aluwini, Wouter V. Vogel, Martijn P. Lolkema, Tom van der Hulle, James Nagaraj, Tom W. J. Scheenen, Guido Jenster, Hans M. Westgeest, Jules Lavalaye, Ivo G. Schoots, Eva E. Schaake, Inge M. van Oort, Daniela E. Oprea-Lager, Gisele H. J. M. Leyten, Irma M. Oving, Pim J. van Leeuwen, Luc M.F. Moonen, Theo M. de Reijke, Derya Yakar, Igle-Jan de Jong, Martijn B. Busstra, Kim de Vries, Henk G. van der Poel, Walter Noordzij, Susanne Osanto, Diederik M. Somford, Franchette W P J van den Berkmortel

Publikováno v: European Urology Oncology, 3(2), 231-238. Elsevier BV
European Urology Oncology, 3, 2, pp. 231-238
European Urology Oncology, 3(2), 231
European urology oncology, 3(2), 231-238. Elsevier BV
European Urology Oncology, 3, 231-238
European urology oncology, 3(2), 231-238. De Tijdstroom/Elsevier
Aluwini, S S, Mehra, N, Lolkema, M P, Oprea-Lager, D E, Yakar, D, Stoevelaar, H, van der Poel, H & Dutch Oligometastatic Prostate Cancer Working Group 2020, ' Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting ', European Urology Oncology, vol. 3, no. 2, pp. 231-238 . https://doi.org/10.1016/j.euo.2019.07.010

Background: Oligometastatic prostate cancer (OMPC) is a heterogeneous disease state that is imperfectly understood, and its clinical implications are unclear. Objective: To determine the consensus of a Dutch multidisciplinary expert panel on biologic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::390966b021c7986598ea8e978b115ad1
https://doi.org/10.1016/j.euo.2019.07.010

Validatie van een nieuwe urinetest voor klinisch significante prostaatkanker

Autor: Frank Smit, Henk Vergunst, Inge M. van Oort, Sander A. Jannink, Theo M. de Reijke, Christina A. Hulsbergen-van de Kaa, Erik B. Cornel, Rianne J. Hendriks, Hans de Jong, Ben C. Knipscheer, Gisele H. J. M. Leyten, Peter F.A. Mulders, Jack A. Schalken, Willem J. G. Melchers, Paul J.M. Kil, Siebren Dijkstra, Daphne Hessels

Publikováno v: Tijdschrift voor Urologie, 6, 34-43
Tijdschrift voor Urologie, 6, pp. 34-43
Tijdschrift voor urologie, 6(2), 34-43. Springer Science + Business Media

Om overdiagnostiek en overbehandeling te verminderen, is er dringend behoefte aan een test voor detectie van klinisch significant prostaatcarcinoom. In deze studie werd een model ontwikkeld (met behulp van geidentificeerde biomarkers HOXC6, DLX1, TDR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3be920739d2784654ec445b674d82475
https://hdl.handle.net/2066/171910

Prostate cancer biomarker profiles in urinary sediments and exosomes

Autor: Ingrid L. Birker, Frank Smit, Inge M. van Oort, Theo M. de Reijke, Peter F.A. Mulders, Siebren Dijkstra, Sander A. Jannink, Jack A. Schalken, Gisele H. J. M. Leyten

Publikováno v: Journal of Urology, 191, 1132-8
Journal of urology, 191(4), 1132-1138. Elsevier Inc.
Journal of Urology, 191, 4, pp. 1132-8

Contains fulltext : 136616.pdf (Publisher’s version ) (Open Access) PURPOSE: Urinary biomarker tests for diagnosing prostate cancer have gained considerable interest. Urine is a complex mixture that can be subfractionated. We evaluated 2 urinary fr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33cb9afa67f12b3ca68d87746106500d
https://hdl.handle.net/2066/136616

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score

Autor: Geert Trooskens, Rianne J. Hendriks, Henk Vergunst, Wim Van Criekinge, Frank Smit, Leander Van Neste, Erik B. Cornel, Gisele H. J. M. Leyten, Hans de Jong, Peter F.A. Mulders, Sander A. Jannink, Christina A. Hulsbergen-van de Kaa, Ben C. Knipscheer, Jack A. Schalken, Willem J. G. Melchers, Daphne Hessels, Paul J.M. Kil, Siebren Dijkstra, Inge M. van Oort, Theo M. de Reijke

Publikováno v: European urology, 70(5), 740-748. Elsevier
European Urology, 70, 5, pp. 740-8
European Urology, 70, 740-8
European Urology, 70(5), 740-748. Elsevier

Background To reduce overdiagnosis and overtreatment, a test is urgently needed to detect clinically significant prostate cancer (PCa). Objective To develop a multimodal model, incorporating previously identified messenger RNA (mRNA) biomarkers and t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f956965b972104fed2d2c3cfe7e4efc1
https://pubmed.ncbi.nlm.nih.gov/27234996

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer

Autor: Sander A. Jannink, Inge M. van Oort, Peter F.A. Mulders, Christina A. Hulsbergen-van de Kaa, Henk Vergunst, Theo M. de Reijke, Frank Smit, Ben C. Knipscheer, Jack A. Schalken, Hans de Jong, Erik B. Cornel, Paul J.M. Kil, Gisele H. J. M. Leyten, Daphne Hessels

Publikováno v: European urology, 65(3), 534-542. Elsevier
European Urology, 65, 534-42
European Urology, 65, 3, pp. 534-42

Contains fulltext : 136611.pdf (Publisher’s version ) (Closed access) BACKGROUND: Prostate cancer antigen 3 (PCA3) and v-ets erythroblastosis virus E26 oncogene homolog (TMPRSS2-ERG) gene fusions are promising prostate cancer (PCa) specific biomark

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5175f674240004a8cc5d519e5e14db6a
https://doi.org/10.1016/j.eururo.2012.11.014